Novo Nordisk exits R&D in inflammatory disorders


On September 2, 2014, Novo Nordisk officially announced its decision to discontinue all its R&D activities within inflammatory disorders.

The company said that it will increase its focus and efforts more within diabetes prevention and treatment, obesity and diabetes complications.

1 Comment Comment 1 - 1 of 1

Gopal Panday 3 February 2015 at 10:23 PM



Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email